Scientific paper - Original scientific paper
Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
Biomedicines, 11 (2023), 5; 1301. https://doi.org/10.3390/biomedicines11051301


Cite this document

Krečak, I., Pivac, Lj., Lucijanić, M. & Skelin, M. (2023). Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms. Biomedicines, 11. (5). doi: 10.3390/biomedicines11051301

Krečak, Ivan, et al. "Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms." Biomedicines, vol. 11, no. 5, 2023. https://doi.org/10.3390/biomedicines11051301

Krečak, Ivan, Ljerka Pivac, Marko Lucijanić and Marko Skelin. "Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms." Biomedicines 11, no. 5 (2023). https://doi.org/10.3390/biomedicines11051301

Krečak, I., et al. (2023) 'Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms', Biomedicines, 11(5). doi: 10.3390/biomedicines11051301

Krečak I, Pivac Lj, Lucijanić M, Skelin M. Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms. Biomedicines [Internet]. 2023 April 27 [cited 2024 February 29];11(5). doi: 10.3390/biomedicines11051301

I. Krečak, Lj. Pivac, M. Lucijanić and M. Skelin, "Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms", Biomedicines, vol. 11, no. 5, April 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:727819. [Accessed: 29 February 2024]

Please login to the repository to save this object to your list.